Compare Cassava Sciences Inc (FLNA) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Philip Morris International Inc. — how do they compare? Cassava Sciences Inc trades at $1.06 (market cap $53.14M), while Philip Morris International Inc. trades at $188.58 (market cap $281.91B). The key difference: Philip Morris International Inc. is far larger — about 5305× Cassava Sciences Inc's market cap, and Philip Morris International Inc. pays a 3.25% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | PM | |
|---|---|---|
Market Cap | $53.14M | $281.91B |
Sector | Health | Consumer Staples |
52-Week High | $4.64 | $191.86 |
52-Week Low | $1.09 | $144.33 |
Enterprise Value | -$33.43M | $328.41B |
Dividend Yield | — | 3.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Philip Morris International (PM) trades at $175.95, down 2.35% amid a bearish technical signal and recent profit forecast revision. The company reported strong Q1 2026 EPS of $1.96, beating estimates, but faces headwinds from a $500 million impairment charge and margin pressures. Revenue growth remains steady, with 2025 revenue at $40.65 billion and net income margin of 26.74%. Analyst consensus is bullish with a $194 price target, though technical indicators show resistance near $179.
The stock presents a mixed outlook: solid fundamentals and high analyst buy ratings support upside potential, but near-term risks include cost pressures, currency volatility, and illicit market growth. Long-term investors may find value in the dividend and brand strength, while caution is warranted due to regulatory and macroeconomic challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
